LIDDS: Patent term extension until 2032 for NanoZolid® technology

LIDDS: Patent term extension until 2032 for NanoZolid® technology
14 December, 2017

An external analysis concludes that a five years patent extension is expected in Europe and predicts a similar extension procedure in the US provided that the pharmaceutical substances in NanoZolid based products are not on the market.

The patent term extension for the technology patent covering NanoZolid in combination with non-marketed active substances can include 2-hydroxyflutamide for treatment of localized prostate cancer (Liproca® Depot) or other products under development by LIDDS. The five year patent extension until 2032 can be expected in Europe and predicts a similar procedure in the US.  In Europe the extension is called Supplementary Patent Certificate (SPC) and the corresponding US procedure is labelled Patent Term Extension (PTE). For the PTE the exact extension term cannot be determined in advance, as it depends on the duration of the regulatory review in the US. Similar patent term extension procedures exist in key markets in Asia and South America.

For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, monica.wallter@liddspharma.com                     

LIDDS is required to disclose the information in this press release under the European Union’s Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 14 December 2017 at 12.15 CET.  
                
About LIDDS
LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid can be combined with both large and small pharmaceutical molecules. The company’s most advanced project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North. Redeye AB is a certified adviser to LIDDS. For more information, go to www.liddspharma.com.